Register for free to
view the full innovation profile.
Vaccines stimulate mucosal T cell responses that are both high avidity (high quality) and high magnitude, while also generating strong B cell responses to HIV-1 antigens.
About
ANU has developed two novel HIV vaccines which dramatically improve both mucosal and systemic immunity in animal models when compared to previous HIV vaccines, by stimulating mucosal T cell responses that are both high avidity (high quality) and high magnitude, while also generating strong B cell responses to HIV-1 antigens. No mucosal HIV vaccine has so far entered clinical trials. The mucosal focus of the new vaccines, and their dual enhancement of T cell and B cell immunity are unique in the context of an HIV vaccine. They offer exciting prospects for a prophylactic and/or therapeutic mucosal HIV-1 vaccine and also vaccines for other chronic mucosal infections such as tuberculosis and chlamydia.